Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia

NCT04605484 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT04605484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Lead sponsor
AlloVir
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2021
Completion date
October 20, 2022
Enrollment
61 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

bk virus infection, bk virus nephropathy